---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037893"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T10:03:47.347523+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TOI reports Q3 revenue $82M (+26% YoY), net loss widens to $17.4M from $2.7M

## Summary
- Revenue $82M (+26% YoY); gross profit $16M (+23% YoY); gross margin 19.5% (down from 20.0%).
- Net loss $17.4M ($0.19 diluted loss) vs $2.7M loss ($0.03 loss) prior year; Adjusted EBITDA loss $(5.3)M vs $(6.7)M.
- Cash and investments $87.4M as of Sept 30, 2023.
- Opened 70th clinic, added 5 physicians (total 112); signed full-risk capitated contract in South Florida effective Jan 1, 2024.
- Reaffirmed full year 2023 guidance.

## SEC filing metadata
- accession: 0001628280-23-037893
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000162828023037893/0001628280-23-037893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000162828023037893/toi-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037893
- JSON: https://secwatch.observer/filing/0001628280-23-037893.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037893.txt

## Key facts
- Earnings Releases
  Oncology Institute, Inc. reported three months ended September 30, 2023 results: revenue $82 million, net income Net loss of $17.4 million, EPS $(0.19). Guidance reaffirmed.
  - Period: three months ended September 30, 2023
  - Revenue: $82 million
  - Net income: Net loss of $17.4 million
  - EPS: $(0.19)
  - Guidance: reaffirmed
  - Result: reported results
  source text: new Chief Operating Officer • Signed full-risk capitated contract in South Florida, effective January 1, 2024 Third Quarter 2023 Financial Highlights • Consolidated revenue of $82 million, an increase of 26% compared to the prior year quarter • Gross profit of $16 million, an increase of 23% compared to the prior year quarter, and gross margin of 19.5%, a decrease
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000162828023037893/0001628280-23-037893-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.